AU6335600A - A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride - Google Patents

A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride

Info

Publication number: AU6335600A
Authority: AU; Australia
Prior art keywords: piperidin; benzo; phenoxy; ethoxy; hydroxy
Prior art date: 1999-07-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU63356/00A

Inventor

Julie Kay Bush

Preston Charles Conrad

Merlyn Gerard Flom

Wayne Douglas Luke

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co

Original Assignee

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-29

Filing date

2000-07-17

Publication date

2001-02-19

2000-07-17 Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co

2001-02-19 Publication of AU6335600A publication Critical patent/AU6335600A/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU63356/00A 1999-07-29 2000-07-17 A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride Abandoned AU6335600A (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US14628699P	1999-07-29	1999-07-29
US60/146286		1999-07-29
US14757099P	1999-08-06	1999-08-06
US60/147570		1999-08-06
US14977399P	1999-08-19	1999-08-19
US60/149773		1999-08-19
PCT/US2000/016333 WO2001009116A2 (en)	1999-07-29	2000-07-17	A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE

Publications (1)

Publication Number	Publication Date
AU6335600A true AU6335600A (en)	2001-02-19

Family

ID=27386379

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU63356/00A Abandoned AU6335600A (en)	1999-07-29	2000-07-17	A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride

Country Status (45)

Country	Link
EP (1)	EP1204656A2 (en)
JP (1)	JP2001064277A (en)
KR (1)	KR100697177B1 (en)
CN (1)	CN1138770C (en)
AR (1)	AR031073A1 (en)
AT (1)	AT502318A1 (en)
AU (1)	AU6335600A (en)
BE (1)	BE1013411A3 (en)
BR (1)	BR0003209A (en)
CA (1)	CA2314682A1 (en)
CO (1)	CO5180570A1 (en)
CZ (1)	CZ299311B6 (en)
DE (1)	DE10036854A1 (en)
DK (1)	DK200001151A (en)
DZ (1)	DZ3060A1 (en)
FI (1)	FI20001722A (en)
FR (1)	FR2796944B1 (en)
GB (1)	GB2352717A (en)
GR (1)	GR1004084B (en)
HK (1)	HK1035370A1 (en)
HR (1)	HRP20000503B1 (en)
HU (1)	HUP0003001A2 (en)
ID (1)	ID27078A (en)
IL (1)	IL137553A (en)
IT (1)	IT1318660B1 (en)
LT (1)	LT4790B (en)
LU (1)	LU90617B1 (en)
LV (1)	LV12623B (en)
MD (1)	MD2336G2 (en)
MX (1)	MXPA00007461A (en)
MY (1)	MY128764A (en)
NL (1)	NL1015821C2 (en)
NO (1)	NO20003879L (en)
PE (1)	PE20010385A1 (en)
PL (1)	PL341749A1 (en)
PT (1)	PT102502A (en)
RO (1)	RO121851B1 (en)
SE (1)	SE0002792L (en)
SG (1)	SG91296A1 (en)
SI (1)	SI20426A (en)
SV (1)	SV2002000132A (en)
TR (1)	TR200002206A2 (en)
TW (1)	TWI276437B (en)
UA (1)	UA72885C2 (en)
WO (1)	WO2001009116A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001009115A2 (en) *	1999-07-29	2001-02-08	Eli Lilly And Company	A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
EP1757291A3 (en) *	2000-05-08	2009-07-15	Eli Lilly & Company	Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
JP2003535827A (en) *	2000-05-08	2003-12-02	イーライ・リリー・アンド・カンパニー	Stabilized formulation of 6-hydroxy-3- (4- [2- (piperidin-1-yl) ethoxy] phenoxy) -2- (4-methoxyphenyl) benzo [b] thiophene and its salts
US7122203B2 (en)	2000-05-08	2006-10-17	Eli Lilly And Company	Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
EP1157996A1 (en) *	2000-05-23	2001-11-28	JENAPHARM GmbH	New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on
EA005116B1 (en) *	2000-10-20	2004-10-28	Эли Лилли Энд Компани	A NOVEL CRYSTALLINE FORM OF 6-HUDROXY-3-(4-[2-PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
AU2002230409A1 (en)	2000-11-27	2002-06-03	Eli Lilly And Company	Process for preparing 3-aryl-benzo(b)thiophenes
CA2393720C (en) *	2002-07-12	2010-09-14	Eli Lilly And Company	Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
SI1773811T1 (en) *	2004-07-22	2011-01-31	Lilly Co Eli	A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3989569B2 (en) *	1995-02-28	2007-10-10	イーライリリーアンドカンパニー	Benzothiophene compounds, intermediates, compositions and methods
US5510357A (en)	1995-02-28	1996-04-23	Eli Lilly And Company	Benzothiophene compounds as anti-estrogenic agents
ZA9710262B (en) *	1996-11-19	1999-05-13	Lilly Co Eli	Process for the synthesis of benzothiophenes
ZA982877B (en) *	1997-04-09	1999-10-04	Lilly Co Eli	Treatment of central nervous system disorders with selective estrogen receptor modulators.

2000
- 2000-07-17 AU AU63356/00A patent/AU6335600A/en not_active Abandoned
- 2000-07-17 EP EP00950223A patent/EP1204656A2/en not_active Ceased
- 2000-07-17 WO PCT/US2000/016333 patent/WO2001009116A2/en not_active Application Discontinuation
- 2000-07-18 LV LVP-00-94A patent/LV12623B/en unknown
- 2000-07-21 RO ROA200000736A patent/RO121851B1/en unknown
- 2000-07-24 CZ CZ20002716A patent/CZ299311B6/en not_active IP Right Cessation
- 2000-07-24 ID IDP20000629D patent/ID27078A/en unknown
- 2000-07-25 HR HR20000503A patent/HRP20000503B1/en not_active IP Right Cessation
- 2000-07-27 IL IL13755300A patent/IL137553A/en not_active IP Right Cessation
- 2000-07-27 NL NL1015821A patent/NL1015821C2/en not_active IP Right Cessation
- 2000-07-27 TR TR2000/02206A patent/TR200002206A2/en unknown
- 2000-07-27 CO CO00056521A patent/CO5180570A1/en active IP Right Grant
- 2000-07-28 IT IT2000MI001759A patent/IT1318660B1/en active
- 2000-07-28 FI FI20001722A patent/FI20001722A/en unknown
- 2000-07-28 MD MDA20000162A patent/MD2336G2/en not_active IP Right Cessation
- 2000-07-28 HU HU0003001A patent/HUP0003001A2/en unknown
- 2000-07-28 FR FR0009969A patent/FR2796944B1/en not_active Expired - Fee Related
- 2000-07-28 PT PT102502A patent/PT102502A/en not_active IP Right Cessation
- 2000-07-28 LU LU90617A patent/LU90617B1/en active
- 2000-07-28 AR ARP000103928A patent/AR031073A1/en unknown
- 2000-07-28 JP JP2000228939A patent/JP2001064277A/en active Pending
- 2000-07-28 BR BR0003209-3A patent/BR0003209A/en not_active Application Discontinuation
- 2000-07-28 NO NO20003879A patent/NO20003879L/en not_active Application Discontinuation
- 2000-07-28 KR KR1020000043651A patent/KR100697177B1/en not_active IP Right Cessation
- 2000-07-28 SV SV2000000132A patent/SV2002000132A/en unknown
- 2000-07-28 CA CA002314682A patent/CA2314682A1/en not_active Abandoned
- 2000-07-28 MX MXPA00007461A patent/MXPA00007461A/en active IP Right Grant
- 2000-07-28 SI SI200000172A patent/SI20426A/en not_active IP Right Cessation
- 2000-07-28 SE SE0002792A patent/SE0002792L/en unknown
- 2000-07-28 CN CNB001222376A patent/CN1138770C/en not_active Expired - Fee Related
- 2000-07-28 GB GB0018641A patent/GB2352717A/en not_active Withdrawn
- 2000-07-28 AT AT0132400A patent/AT502318A1/en not_active Application Discontinuation
- 2000-07-28 PL PL00341749A patent/PL341749A1/en not_active Application Discontinuation
- 2000-07-28 LT LT2000076A patent/LT4790B/en not_active IP Right Cessation
- 2000-07-28 DK DK200001151A patent/DK200001151A/en not_active Application Discontinuation
- 2000-07-28 MY MYPI20003453A patent/MY128764A/en unknown
- 2000-07-28 SG SG200004288A patent/SG91296A1/en unknown
- 2000-07-28 GR GR20000100265A patent/GR1004084B/en unknown
- 2000-07-28 TW TW089115154A patent/TWI276437B/en not_active IP Right Cessation
- 2000-07-28 BE BE2000/0478A patent/BE1013411A3/en not_active IP Right Cessation
- 2000-07-28 UA UA2000074563A patent/UA72885C2/en unknown
- 2000-07-28 DE DE10036854A patent/DE10036854A1/en not_active Withdrawn
- 2000-07-29 DZ DZ000126A patent/DZ3060A1/en active
- 2000-07-31 PE PE2000000757A patent/PE20010385A1/en not_active Application Discontinuation
2001
- 2001-09-03 HK HK01106204A patent/HK1035370A1/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI20001722A0 (en)	2000-07-28
ITMI20001759A1 (en)	2002-01-28
IT1318660B1 (en)	2003-08-27
KR100697177B1 (en)	2007-03-21
BE1013411A3 (en)	2001-12-04
HK1035370A1 (en)	2001-11-23
WO2001009116A2 (en)	2001-02-08
TR200002206A2 (en)	2001-03-21
PT102502A (en)	2001-01-31
FR2796944B1 (en)	2003-01-31
EP1204656A2 (en)	2002-05-15
MD20000162A (en)	2001-04-30
FI20001722A (en)	2001-01-30
FR2796944A1 (en)	2001-02-02
NO20003879D0 (en)	2000-07-28
HU0003001D0 (en)	2000-10-28
ITMI20001759A0 (en)	2000-07-28
CO5180570A1 (en)	2002-07-30
CN1288007A (en)	2001-03-21
HRP20000503B1 (en)	2008-04-30
SE0002792D0 (en)	2000-07-28
DZ3060A1 (en)	2004-05-22
DE10036854A1 (en)	2001-03-01
TWI276437B (en)	2007-03-21
MD2336G2 (en)	2004-06-30
IE20000605A1 (en)	2001-04-04
CZ299311B6 (en)	2008-06-18
PL341749A1 (en)	2001-02-12
LV12623A (en)	2001-03-20
MY128764A (en)	2007-02-28
LT2000076A (en)	2001-02-26
SV2002000132A (en)	2002-06-07
GR1004084B (en)	2002-12-11
DK200001151A (en)	2001-01-30
SG91296A1 (en)	2002-09-17
IL137553A0 (en)	2001-07-24
IL137553A (en)	2005-09-25
LV12623B (en)	2001-07-20
LU90617B1 (en)	2001-06-15
CA2314682A1 (en)	2001-01-29
ID27078A (en)	2001-02-22
SE0002792L (en)	2001-01-30
NL1015821C2 (en)	2002-01-03
LT4790B (en)	2001-05-25
JP2001064277A (en)	2001-03-13
MD2336F2 (en)	2003-12-31
AT502318A1 (en)	2007-02-15
GB2352717A (en)	2001-02-07
CZ20002716A3 (en)	2001-05-16
MXPA00007461A (en)	2004-07-16
UA72885C2 (en)	2005-05-16
BR0003209A (en)	2001-03-20
WO2001009116A3 (en)	2001-05-17
AR031073A1 (en)	2003-09-10
NO20003879L (en)	2001-01-30
CN1138770C (en)	2004-02-18
GB0018641D0 (en)	2000-09-13
GR20000100265A (en)	2001-03-30
HUP0003001A2 (en)	2002-04-29
HRP20000503A2 (en)	2001-06-30
RO121851B1 (en)	2008-06-30
SI20426A (en)	2001-06-30
PE20010385A1 (en)	2001-04-06
NL1015821A1 (en)	2001-01-30
KR20010049916A (en)	2001-06-15

Publication	Publication Date	Title
AU6335500A (en)	2001-02-19	A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
AU6335600A (en)	2001-02-19	A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
IL155487A0 (en)	2003-11-23	A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
AU4604000A (en)	2000-12-12	Amorphous form of fexofenadine hydrochloride
CY2344B1 (en)	2004-06-04	A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
ZA200003838B (en)	2002-01-28	A novel chrystalline form of 6-hydroxy-3-(4-[2-)piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride.
IL152699A0 (en)	2003-06-24	STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO [b] THIOPHENE AND SALTS THEREOF
TJ20000620A (en)	2002-07-01	A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxy Ü phenoxy) - 2 - (4-methanoxyphenyl) benzo ÄbÜ thiophene hidrochloride
TJ20000619A (en)	2002-07-01	A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl) ethoxyÜ phenoxy) -2- (4-methanoxyphenyl) benzoÄbÜ thiophene hidrochloride

Legal Events

Date	Code	Title	Description
2002-05-02	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase